Abeona Capital Expenditures vs End Period Cash Flow Analysis

ABEO Stock

USD 6.41 0.38 6.30%

Abeona Therapeutics financial indicator trend analysis is way more than just evaluating Abeona Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Abeona Therapeutics is a good investment. Please check the relationship between Abeona Therapeutics Capital Expenditures and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.

Capital Expenditures vs End Period Cash Flow

Capital Expenditures vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Abeona Therapeutics Capital Expenditures account and End Period Cash Flow. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Abeona Therapeutics' Capital Expenditures and End Period Cash Flow is 0.13. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Abeona Therapeutics, assuming nothing else is changed. The correlation between historical values of Abeona Therapeutics' Capital Expenditures and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Abeona Therapeutics are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Abeona Therapeutics' Capital Expenditures and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.13

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Abeona Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Abeona Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

End Period Cash Flow

Most indicators from Abeona Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Abeona Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.At this time, Abeona Therapeutics' Issuance Of Capital Stock is very stable compared to the past year. As of the 30th of November 2024, Sales General And Administrative To Revenue is likely to grow to 10.49, while Selling General Administrative is likely to drop about 18.1 M.

Abeona Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Term Debt	Intangible Assets
Total Assets		0.68	0.58	0.65	0.98	-0.66	-0.31	0.7	0.76	0.97	-0.19	0.34	-0.03	-0.1	-0.4	0.54	0.43	0.39	0.97	0.48	0.57	0.93	0.66	0.42	0.06	0.7
Short Long Term Debt Total	0.68		-0.03	0.12	0.73	-0.48	-0.1	0.62	0.56	0.69	-0.14	0.05	-0.06	-0.08	-0.31	0.28	0.3	0.03	0.69	0.17	0.08	0.59	0.04	0.01	-0.08	0.47
Other Current Liab	0.58	-0.03		0.95	0.47	-0.27	-0.33	0.46	0.31	0.54	-0.08	0.46	0.04	-0.14	-0.23	0.49	0.16	0.58	0.55	0.56	0.72	0.56	0.95	0.6	0.15	0.31
Total Current Liabilities	0.65	0.12	0.95		0.53	-0.16	-0.4	0.68	0.24	0.58	-0.03	0.48	0.04	-0.04	-0.23	0.62	0.12	0.69	0.59	0.61	0.8	0.67	0.88	0.65	0.4	0.47
Total Stockholder Equity	0.98	0.73	0.47	0.53		-0.75	-0.17	0.63	0.83	0.96	-0.25	0.22	-0.13	-0.22	-0.49	0.47	0.44	0.22	0.95	0.44	0.45	0.9	0.59	0.28	-0.08	0.67
Net Debt	-0.66	-0.48	-0.27	-0.16	-0.75		-0.01	-0.11	-0.99	-0.74	0.19	-0.03	0.16	0.36	0.36	-0.13	-0.25	0.14	-0.73	-0.22	-0.14	-0.48	-0.43	-0.03	0.6	-0.27
Retained Earnings	-0.31	-0.1	-0.33	-0.4	-0.17	-0.01		-0.4	-0.06	-0.35	-0.64	-0.92	-0.77	-0.76	-0.48	-0.47	-0.32	-0.84	-0.37	-0.36	-0.69	-0.14	-0.36	-0.86	-0.3	-0.01
Accounts Payable	0.7	0.62	0.46	0.68	0.63	-0.11	-0.4		0.25	0.6	0.1	0.35	0.0	0.05	-0.32	0.72	0.18	0.53	0.62	0.61	0.64	0.74	0.42	0.49	0.51	0.63
Cash	0.76	0.56	0.31	0.24	0.83	-0.99	-0.06	0.25		0.82	-0.18	0.1	-0.12	-0.3	-0.38	0.22	0.3	-0.04	0.81	0.28	0.23	0.6	0.46	0.12	-0.47	0.4
Cash And Short Term Investments	0.97	0.69	0.54	0.58	0.96	-0.74	-0.35	0.6	0.82		-0.16	0.38	0.03	-0.09	-0.31	0.49	0.43	0.35	1.0	0.42	0.52	0.81	0.66	0.4	-0.08	0.54
Net Receivables	-0.19	-0.14	-0.08	-0.03	-0.25	0.19	-0.64	0.1	-0.18	-0.16		0.63	0.72	0.61	0.46	0.37	0.03	0.43	-0.12	0.37	0.35	-0.3	-0.07	0.63	0.19	-0.28
Common Stock Total Equity	0.34	0.05	0.46	0.48	0.22	-0.03	-0.92	0.35	0.1	0.38	0.63		0.78	0.66	0.47	0.5	0.41	0.83	0.41	0.46	0.76	0.17	0.5	0.94	0.25	0.01
Common Stock Shares Outstanding	-0.03	-0.06	0.04	0.04	-0.13	0.16	-0.77	0.0	-0.12	0.03	0.72	0.78		0.88	0.73	0.01	0.25	0.68	0.04	-0.05	0.25	-0.19	0.11	0.67	0.13	-0.17
Non Current Liabilities Total	-0.1	-0.08	-0.14	-0.04	-0.22	0.36	-0.76	0.05	-0.3	-0.09	0.61	0.66	0.88		0.81	-0.05	0.09	0.7	-0.08	-0.2	0.21	-0.17	-0.11	0.56	0.42	-0.03
Inventory	-0.4	-0.31	-0.23	-0.23	-0.49	0.36	-0.48	-0.32	-0.38	-0.31	0.46	0.47	0.73	0.81		-0.33	-0.24	0.43	-0.31	-0.41	-0.04	-0.51	-0.19	0.29	0.21	-0.36
Other Current Assets	0.54	0.28	0.49	0.62	0.47	-0.13	-0.47	0.72	0.22	0.49	0.37	0.5	0.01	-0.05	-0.33		0.26	0.41	0.54	0.94	0.82	0.48	0.47	0.63	0.38	0.24
Other Stockholder Equity	0.43	0.3	0.16	0.12	0.44	-0.25	-0.32	0.18	0.3	0.43	0.03	0.41	0.25	0.09	-0.24	0.26		0.16	0.44	0.26	0.33	0.36	0.22	0.36	-0.2	0.22
Total Liab	0.39	0.03	0.58	0.69	0.22	0.14	-0.84	0.53	-0.04	0.35	0.43	0.83	0.68	0.7	0.43	0.41	0.16		0.36	0.3	0.72	0.35	0.56	0.88	0.58	0.31
Total Current Assets	0.97	0.69	0.55	0.59	0.95	-0.73	-0.37	0.62	0.81	1.0	-0.12	0.41	0.04	-0.08	-0.31	0.54	0.44	0.36		0.46	0.55	0.81	0.66	0.43	-0.06	0.54
Common Stock	0.48	0.17	0.56	0.61	0.44	-0.22	-0.36	0.61	0.28	0.42	0.37	0.46	-0.05	-0.2	-0.41	0.94	0.26	0.3	0.46		0.81	0.44	0.53	0.61	0.19	0.17
Property Plant And Equipment Net	0.57	0.08	0.72	0.8	0.45	-0.14	-0.69	0.64	0.23	0.52	0.35	0.76	0.25	0.21	-0.04	0.82	0.33	0.72	0.55	0.81		0.53	0.69	0.88	0.43	0.35
Non Current Assets Total	0.93	0.59	0.56	0.67	0.9	-0.48	-0.14	0.74	0.6	0.81	-0.3	0.17	-0.19	-0.17	-0.51	0.48	0.36	0.35	0.81	0.44	0.53		0.58	0.32	0.23	0.86
Non Currrent Assets Other	0.66	0.04	0.95	0.88	0.59	-0.43	-0.36	0.42	0.46	0.66	-0.07	0.5	0.11	-0.11	-0.19	0.47	0.22	0.56	0.66	0.53	0.69	0.58		0.6	0.04	0.29
Property Plant And Equipment Gross	0.42	0.01	0.6	0.65	0.28	-0.03	-0.86	0.49	0.12	0.4	0.63	0.94	0.67	0.56	0.29	0.63	0.36	0.88	0.43	0.61	0.88	0.32	0.6		0.39	0.21
Short Term Debt	0.06	-0.08	0.15	0.4	-0.08	0.6	-0.3	0.51	-0.47	-0.08	0.19	0.25	0.13	0.42	0.21	0.38	-0.2	0.58	-0.06	0.19	0.43	0.23	0.04	0.39		0.43
Intangible Assets	0.7	0.47	0.31	0.47	0.67	-0.27	-0.01	0.63	0.4	0.54	-0.28	0.01	-0.17	-0.03	-0.36	0.24	0.22	0.31	0.54	0.17	0.35	0.86	0.29	0.21	0.43

Click cells to compare fundamentals

Abeona Therapeutics Account Relationship Matchups

Abeona Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	223.4M	151.2M	79.6M	64.2M	64.0M	49.3M
Short Long Term Debt Total	8.0M	8.7M	9.4M	7.6M	5.4M	7.9M
Other Current Liab	32.9M	33.2M	8.4M	2.4M	9.6M	5.1M
Total Current Liabilities	38.7M	42.0M	16.6M	7.8M	13.4M	9.8M
Total Stockholder Equity	178.4M	102.6M	51.4M	26.8M	14.8M	28.6M
Net Debt	(121.3M)	(3.9M)	(23.6M)	(6.6M)	(9.1M)	(9.5M)
Retained Earnings	(486.5M)	(570.7M)	(655.6M)	(695.3M)	(749.5M)	(712.0M)
Accounts Payable	3.8M	4.7M	4.3M	1.8M	1.9M	2.5M
Cash	129.3M	12.6M	32.9M	14.2M	14.5M	19.9M
Cash And Short Term Investments	129.3M	95.0M	45.0M	52.1M	52.2M	30.8M
Common Stock Total Equity	469K	479K	836K	961K	1.1M	1.2M
Common Stock Shares Outstanding	2.0M	3.7M	3.9M	7.9M	21.4M	22.4M
Liabilities And Stockholders Equity	223.4M	151.2M	79.6M	64.2M	64.0M	49.3M
Non Current Liabilities Total	6.3M	6.7M	11.6M	29.7M	35.8M	37.5M
Other Current Assets	3.1M	5.4M	8.3M	762K	1.1M	1.2M
Other Stockholder Equity	664.1M	672.3M	705.6M	722.0M	764.2M	802.4M
Total Liab	45.0M	48.6M	28.2M	37.5M	49.2M	51.6M
Total Current Assets	132.4M	97.7M	56.3M	53.1M	55.7M	32.7M
Common Stock	836K	961K	1.5M	177K	265K	417.6K
Property Plant And Equipment Net	21.2M	18.4M	21.7M	11.1M	8.0M	8.4M
Non Current Assets Total	91.0M	53.5M	23.3M	11.1M	8.3M	7.9M
Non Currrent Assets Other	1.1M	1.1M	168K	43K	277K	319.9K
Property Plant And Equipment Gross	21.2M	18.4M	21.7M	11.1M	21.0M	22.0M
Short Term Debt	1.7M	3.8M	3.6M	3.5M	2.0M	2.5M
Intangible Assets	43.0M	36.2M	1.5M	1.4M	1.6M	1.5M
Other Assets	1.1M	1.1M	1.1M	43K	38.7K	36.8K
Property Plant Equipment	13.2M	18.4M	21.7M	11.1M	12.7M	13.4M
Other Liab	3.1M	20M	4.0M	23.8M	27.4M	28.8M
Retained Earnings Total Equity	(359.8M)	(410.2M)	(486.5M)	(570.7M)	(513.6M)	(488.0M)
Net Tangible Assets	178.4M	68.6M	50.0M	26.8M	30.8M	29.2M
Capital Surpluse	529.4M	543.8M	664.1M	672.3M	773.1M	518.5M

Pair Trading with Abeona Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abeona Stock

0.78	EWTX	Edgewise Therapeutics	Pair Corr
0.64	BHC	Bausch Health Companies	Pair Corr

Moving against Abeona Stock

0.52	ELAN	Elanco Animal Health	Pair Corr
0.46	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.46	INAB	In8bio Inc	Pair Corr
0.35	HLN	Haleon plc	Pair Corr
0.34	TAK	Takeda Pharmaceutical	Pair Corr

The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.

The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock:

How To Invest In Abeona

Details

Is Abeona Stock a good investment?

Details

What is Abeona Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.05)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.38)

Return On Equity

(1.27)

The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Abeona Capital Expenditures vs End Period Cash Flow Analysis

Capital Expenditures vs End Period Cash Flow

Capital Expenditures vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Capital Expenditures

End Period Cash Flow

Abeona Therapeutics fundamental ratios Correlations

Abeona Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Abeona Therapeutics fundamental ratios Accounts

Pair Trading with Abeona Therapeutics

Moving together with Abeona Stock

Moving against Abeona Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.97	Total Assets
Total Current Assets	+ 0.97	Total Assets
Cash And Short Term Investments	+ 0.96	Total Stockholder Equity
Total Current Liabilities	+ 0.95	Other Current Liab

Cash	- 0.99	Net Debt
Common Stock Total Equity	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.86	Retained Earnings
Total Liab	- 0.84	Retained Earnings
Common Stock Shares Outstanding	- 0.77	Retained Earnings
Non Current Liabilities Total	- 0.76	Retained Earnings